16 related articles for article (PubMed ID: 31508747)
1. Sociodemographic and Geographic Disparities of Prostate Cancer Treatment Delay in Tennessee: A Population-Based Study.
Montiel Ishino FA; Odame EA; Villalobos K; Rowan C; Whiteside M; Mamudu H; Williams F
Am J Mens Health; 2021; 15(6):15579883211057990. PubMed ID: 34836465
[TBL] [Abstract][Full Text] [Related]
2. Self-care related to the performance of occupational roles in patients under antineoplastic chemotherapy treatment.
Chagas LMO; Sabino FHO; Barbosa MH; Frizzo HCF; Andrade LF; Barichello E
Rev Lat Am Enfermagem; 2021; 29():e3421. PubMed ID: 34037118
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer outcomes and delays in care.
O'Callaghan ME; Shi Z; Kopsaftis T; Moretti K
Int Urol Nephrol; 2017 Mar; 49(3):449-455. PubMed ID: 28083860
[TBL] [Abstract][Full Text] [Related]
5. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
6. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
7. [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?].
Meunier ME; Neuzillet Y; Radulescu C; Cherbonnier C; Hervé JM; Rouanne M; Molinié V; Lebret T
Prog Urol; 2018 Sep; 28(10):475-481. PubMed ID: 29907495
[TBL] [Abstract][Full Text] [Related]
8. Association of sociodemographic and clinical variables with time to start prostate cancer treatment.
Sacramento RS; Simião LJ; Viana KCG; Andrade MAC; Amorim MHC; Zandonade E
Cien Saude Colet; 2019 Sep; 24(9):3265-3274. PubMed ID: 31508747
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]